J Cancer Prev.  2015 Jun;20(2):85-91. 10.15430/JCP.2015.20.2.85.

Dual Inhibitors Against Topoisomerases and Histone Deacetylases

Affiliations
  • 1College of Pharmacy, Keimyung University, Daegu, Korea. seoyho@kmu.ac.kr

Abstract

Topoisomerases and histone deacetylases (HDACs) are considered as important therapeutic targets for a wide range of cancers, due to their association with the initiation, proliferation and survival of cancer cells. Topoisomerases are involved in the cleavage and religation processes of DNA, while HDACs regulate a dynamic epigenetic modification of the lysine amino acid on various proteins. Extensive studies have been undertaken to discover small molecule inhibitor of each protein and thereby, several drugs have been transpired from this effort and successfully approved for clinical use. However, the inherent heterogeneity and multiple genetic abnormalities of cancers challenge the clinical application of these single targeted drugs. In order to overcome the limitations of a single target approach, a novel approach, simultaneously targeting topoisomerases and HDACs with a single molecule has been recently employed and attracted much attention of medicinal chemists in drug discovery. This review highlights the current studies on the discovery of dual inhibitors against topoisomerases and HDACs, provides their pharmacological aspects and advantages, and discusses the challenges and promise of the dual inhibitors.

Keyword

Dual inhibitor; Topoisomerase; Histone deacetylases; Small molecule

MeSH Terms

DNA
Drug Discovery
Epigenomics
Histone Deacetylases*
Histones*
Lysine
Population Characteristics
DNA
Histone Deacetylases
Histones
Lysine
Full Text Links
  • JCP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error